drug · antibody

ZYNYZ

updated 3mo ago

by $INCY INCYTE CORP🔗 ChEMBL

community read0 votes

🐶 often sniffed alongside

top 3

Antibody drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 16 investigational indications.

targets

Programmed cell death protein 1

all catalysts(0)

nothing on the calendar yet

News(2)

Scholar Rock ditches Novo’s legacy Catalent plant in FDA refiling of SMA drug
Scholar Rock has dropped Novo Nordisk’s troubled Catalent facility as a contract manufacturer in its FDA refiling for apitegromab, a spinal muscular atrophy candidate, after a recent inspection of…
fiercebiotech · 7d ago
Incyte ditches phase 1-stage JAK inhibitor to pursue next-gen options
Incyte has ditched a JAK2 inhibitor in phase 1 development for a rare blood cancer in favor of “next-generation” replacements.
fiercebiotech · 20d ago

brand

ZYNYZ

trade names

Zynyz

generic

RETIFANLIMAB-DLWR

MOA

12.1 Mechanism of Action Binding of the PD-1 ligands, PD-L1 and PD-L2, to the PD-1 receptor found on T cells, inhibits T-cell proliferation and cytokine production. Upregulation of PD-1 ligands occurs in some tumors, and signaling through this pathway can contribute to inhibition of active T-cell immune surveillance of tumors. Retifanlimab-dlwr binds to the PD-1 receptor, blocks interaction with its ligands PD-L1 and PD‑L2, and potentiates T-cell activity.

indication

1 INDICATIONS AND USAGE ZYNYZ is a programmed death receptor-1 (PD-1)–blocking antibody indicated: Squamous Cell Carcinoma of the Anal Canal (SCAC) in combination with carboplatin and paclitaxel for the first-line treatment of adult patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC). ( 1.1 ) as a single agent for the treatment of adult patients with locally recurrent or metastatic SCAC with disease progression on or intolerance to platinum-based chemotherapy. ( 1.1 ) Merkel Cell Carcinoma (MCC) for the treatment of adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC). ( 1.2 ) 1.1 Squamous Cell Carcinoma of the Anal Canal ZYNYZ, in combination with carboplatin and paclitaxel, is indicated for the first-line treatment of adult patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC). ZYNYZ, as a single agent, is indicated for the treatment of adult patients with locally recurrent or metastatic SCAC with disease progression on or intolerance to platinum‑based chemotherapy. 1.2 Merkel Cell Carcinoma ZYNYZ is indicated for the treatment of adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC).

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 21m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

News(2)

Scholar Rock ditches Novo’s legacy Catalent plant in FDA refiling of SMA drug

Scholar Rock has dropped Novo Nordisk’s troubled Catalent facility as a contract manufacturer in its FDA refiling for apitegromab, a spinal muscular atrophy candidate, after a recent inspection of…

fiercebiotech · 7d ago

Incyte ditches phase 1-stage JAK inhibitor to pursue next-gen options

Incyte has ditched a JAK2 inhibitor in phase 1 development for a rare blood cancer in favor of “next-generation” replacements.

fiercebiotech · 20d ago

ZYNYZ

🐶 often sniffed alongside

targets

all catalysts(0)

News(2)

Report a data issue

comments(0)

ZYNYZ

🐶 often sniffed alongside

targets

all catalysts(0)

News(2)

Report a data issue

comments(0)